A pharmacovigilance study of adverse events associated with polycythemia vera treatments using the FDA Adverse Event Reporting System (FAERS) database.

Ann Hematol · 2025 · PMC12334515 · PMID 40637862

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

a decreasing trendno p-value reported

For non-serious AEs, ropeg exhibited elevated RORs throughout the study period, though the values declined over time: ROR was 5.56 (95% CI: 3.75–8.24) in 2022, 4.34 (95% CI: 3.35–5.63) in 2023, and decreased to 1.79 (95% CI: 1.20–2.69) in 2024, suggesting a decreasing trend in the frequency of reported non-serious AEs over time.

also in 47,180 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.